_id
691859c73c536f8df2317b85
Ticker
0MH6.LSE
Name
Ipsen SA
Exchange
LSE
Address
70 rue Balard, Paris, France, 75015
Country
UK
Sector
Industry
Currency
EUR
Website
https://www.ipsen.com
Description
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injection for the treatment of pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer; Tazverik, a chemotherapy-free EZH2a inhibitor that is in phase III clinical trial for the treatment of second line follicular lymphoma; Tovorafenib that is in phase III clinical trial to treat first line pediatric Low-Grade Gliomas and is In phase II clinical trial for the treatment of relapsed/refractory pediatric Low-Grade Gliomas; and IPN01194 and IPN01195 that is in phase I to treat solid tumors. The company is also developing products for rare disease comprising Bylvay for the treatment of progressive familial intrahepatic cholestasis; Iqirvo, a peroxisome proliferator-activated receptor agonist to treat primary biliary cholangitis; NutropinAq, a liquid formulation of recombinant human growth hormone; Increlex, a recombinant human insulin-like growth factor; Fidrisertib that is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressive; Ritivixibat that is in phase II clinical trial to treat primary sclerosing cholangitis. In addition, it develops neuroscience products, such as Dysport that is in phase III clinical trial for the treatment of chronic and episodic migraine; and IPN10200 that is in phase II to treat aesthetic and therapeutic indications. The company has a partnership with Simcere Zaiming Pharmaceutical Co., Ltd. for the development of SIM0613, a protein expressed on varies tumor types and cancer-associated fibroblasts. The company was founded in 1929 and is headquartered in Paris, France.
Last Close
121.3
Volume
76106
Current Price
120
Change
-0.1
Last Updated
2026-01-08T14:29:01.994Z
Image
https://logo.clearbit.com/www.ipsen.com
Ipo Date
-
Market Cap
7627122000
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Current Quarter
2022-12-31
Revenue
-
Cost Of Revenue
-
Gross Profit
-
Operating Expenses
-
Operating Income
-
Interest Expense
-
Pretax Income
-
Net Income
-
Eps
-
Dividends Per Share
-
Shares Outstanding
0
Income Tax Expense
1900000
EBITDA
-
Operating Margin
-
Total Other Income Expense Net
-
Cash
-
Short Term Investments
-
Receivables
673700000
Inventories
284100000
Total Current Assets
2397600000
Property Plant Equipment
581400000
Total Assets
-
Payables
647100000
Short Term Debt
-
Long Term Debt
-
Total Liabilities
1335400000
Equity
-
Bs_currency_symbol
EUR
Depreciation
59600000
Change In Working Capital
-
Cash From Operations
275800000
Capital Expenditures
24350000
Cash From Investing
-140000000
Cash From Financing
-102550000
Net Change In Cash
62050000
Cf_currency_symbol
EUR
PE
-
PB
-
ROE
-
ROA
-
FCF
251450000
Fcf Percent
-
Piotroski FScore
1
Health Score
46
Deep Value Investing Score
0.5
Defensive Investing Score
5
Dividend Investing Score
1.5
Economic Moat Investing Score
1.5
Garp Investing Score
0
Growth Investing Score
0
Momentum Investing Score
2.5
Net Net Investing Score
0
Quality Investing Score
0.5
Value Investing Score
2
Quarters > 0 > quarter
2022-12-31
Quarters > 0 > income Statement > revenue
-
Quarters > 0 > income Statement > cost Of Revenue
-
Quarters > 0 > income Statement > gross Profit
-
Quarters > 0 > income Statement > operating Expenses
-
Quarters > 0 > income Statement > operating Income
-
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
-
Quarters > 0 > income Statement > net Income
-
Quarters > 0 > income Statement > eps
-
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
-
Quarters > 0 > income Statement > income Tax Expense
1900000
Quarters > 0 > income Statement > EBITDA
-
Quarters > 0 > income Statement > operating Margin
-
Quarters > 0 > income Statement > total Other Income Expense Net
-
Quarters > 0 > income Statement > currency_symbol
EUR
Quarters > 0 > balance Sheet > cash
-
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
673700000
Quarters > 0 > balance Sheet > inventories
284100000
Quarters > 0 > balance Sheet > total Current Assets
2397600000
Quarters > 0 > balance Sheet > property Plant Equipment
581400000
Quarters > 0 > balance Sheet > total Assets
-
Quarters > 0 > balance Sheet > payables
647100000
Quarters > 0 > balance Sheet > short Term Debt
-
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
1335400000
Quarters > 0 > balance Sheet > equity
-
Quarters > 0 > balance Sheet > currency_symbol
EUR
Quarters > 0 > cash Flow > net Income
127150000
Quarters > 0 > cash Flow > depreciation
59600000
Quarters > 0 > cash Flow > change In Working Capital
-
Quarters > 0 > cash Flow > cash From Operations
275800000
Quarters > 0 > cash Flow > capital Expenditures
24350000
Quarters > 0 > cash Flow > cash From Investing
-140000000
Quarters > 0 > cash Flow > cash From Financing
-102550000
Quarters > 0 > cash Flow > net Change In Cash
62050000
Quarters > 0 > cash Flow > currency_symbol
EUR
Quarters > 0 > ratios > PE
-
Quarters > 0 > ratios > PB
-
Quarters > 0 > ratios > ROE
-
Quarters > 0 > ratios > ROA
-
Quarters > 0 > ratios > FCF
251450000
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
46
Quarters > 1 > quarter
2022-09-30
Quarters > 1 > income Statement > revenue
-
Quarters > 1 > income Statement > cost Of Revenue
-
Quarters > 1 > income Statement > gross Profit
-
Quarters > 1 > income Statement > operating Expenses
-
Quarters > 1 > income Statement > operating Income
-
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
-
Quarters > 1 > income Statement > net Income
-
Quarters > 1 > income Statement > eps
-
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
-
Quarters > 1 > income Statement > income Tax Expense
1900000
Quarters > 1 > income Statement > EBITDA
-
Quarters > 1 > income Statement > operating Margin
-
Quarters > 1 > income Statement > total Other Income Expense Net
-
Quarters > 1 > income Statement > currency_symbol
EUR
Quarters > 1 > balance Sheet > cash
-
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
673700000
Quarters > 1 > balance Sheet > inventories
284100000
Quarters > 1 > balance Sheet > total Current Assets
2397600000
Quarters > 1 > balance Sheet > property Plant Equipment
581400000
Quarters > 1 > balance Sheet > total Assets
-
Quarters > 1 > balance Sheet > payables
647100000
Quarters > 1 > balance Sheet > short Term Debt
-
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
1335400000
Quarters > 1 > balance Sheet > equity
-
Quarters > 1 > balance Sheet > currency_symbol
EUR
Quarters > 1 > cash Flow > net Income
127150000
Quarters > 1 > cash Flow > depreciation
59600000
Quarters > 1 > cash Flow > change In Working Capital
-
Quarters > 1 > cash Flow > cash From Operations
275800000
Quarters > 1 > cash Flow > capital Expenditures
24350000
Quarters > 1 > cash Flow > cash From Investing
-140000000
Quarters > 1 > cash Flow > cash From Financing
-102550000
Quarters > 1 > cash Flow > net Change In Cash
62050000
Quarters > 1 > cash Flow > currency_symbol
EUR
Quarters > 1 > ratios > PE
-
Quarters > 1 > ratios > PB
-
Quarters > 1 > ratios > ROE
-
Quarters > 1 > ratios > ROA
-
Quarters > 1 > ratios > FCF
251450000
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
46
Quarters > 2 > quarter
2022-06-30
Quarters > 2 > income Statement > revenue
-
Quarters > 2 > income Statement > cost Of Revenue
-
Quarters > 2 > income Statement > gross Profit
-
Quarters > 2 > income Statement > operating Expenses
-
Quarters > 2 > income Statement > operating Income
-
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
-
Quarters > 2 > income Statement > net Income
-
Quarters > 2 > income Statement > eps
-
Quarters > 2 > income Statement > dividends Per Share
49650000
Quarters > 2 > income Statement > shares Outstanding
-
Quarters > 2 > income Statement > income Tax Expense
54250000
Quarters > 2 > income Statement > EBITDA
-
Quarters > 2 > income Statement > operating Margin
-
Quarters > 2 > income Statement > total Other Income Expense Net
-
Quarters > 2 > income Statement > currency_symbol
EUR
Quarters > 2 > balance Sheet > cash
-
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
772000000
Quarters > 2 > balance Sheet > inventories
190100000
Quarters > 2 > balance Sheet > total Current Assets
2589000000
Quarters > 2 > balance Sheet > property Plant Equipment
585900000
Quarters > 2 > balance Sheet > total Assets
-
Quarters > 2 > balance Sheet > payables
577800000
Quarters > 2 > balance Sheet > short Term Debt
-
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
1374200000
Quarters > 2 > balance Sheet > equity
-
Quarters > 2 > balance Sheet > currency_symbol
EUR
Quarters > 2 > cash Flow > net Income
197150000
Quarters > 2 > cash Flow > depreciation
51500000
Quarters > 2 > cash Flow > change In Working Capital
-
Quarters > 2 > cash Flow > cash From Operations
209900000
Quarters > 2 > cash Flow > capital Expenditures
24100000
Quarters > 2 > cash Flow > cash From Investing
-89300000
Quarters > 2 > cash Flow > cash From Financing
20450000
Quarters > 2 > cash Flow > net Change In Cash
114250000
Quarters > 2 > cash Flow > currency_symbol
EUR
Quarters > 2 > ratios > PE
-
Quarters > 2 > ratios > PB
-
Quarters > 2 > ratios > ROE
-
Quarters > 2 > ratios > ROA
-
Quarters > 2 > ratios > FCF
185800000
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-
Quarters > 2 > health Score
46
Quarters > 3 > quarter
2022-03-31
Quarters > 3 > income Statement > revenue
-
Quarters > 3 > income Statement > cost Of Revenue
-
Quarters > 3 > income Statement > gross Profit
-
Quarters > 3 > income Statement > operating Expenses
-
Quarters > 3 > income Statement > operating Income
-
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-
Quarters > 3 > income Statement > net Income
-
Quarters > 3 > income Statement > eps
-
Quarters > 3 > income Statement > dividends Per Share
49650000
Quarters > 3 > income Statement > shares Outstanding
-
Quarters > 3 > income Statement > income Tax Expense
54250000
Quarters > 3 > income Statement > EBITDA
-
Quarters > 3 > income Statement > operating Margin
-
Quarters > 3 > income Statement > total Other Income Expense Net
-
Quarters > 3 > income Statement > currency_symbol
EUR
Quarters > 3 > balance Sheet > cash
-
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
772000000
Quarters > 3 > balance Sheet > inventories
190100000
Quarters > 3 > balance Sheet > total Current Assets
2589000000
Quarters > 3 > balance Sheet > property Plant Equipment
585900000
Quarters > 3 > balance Sheet > total Assets
-
Quarters > 3 > balance Sheet > payables
577800000
Quarters > 3 > balance Sheet > short Term Debt
-
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
1374200000
Quarters > 3 > balance Sheet > equity
-
Quarters > 3 > balance Sheet > currency_symbol
EUR
Quarters > 3 > cash Flow > net Income
197150000
Quarters > 3 > cash Flow > depreciation
51500000
Quarters > 3 > cash Flow > change In Working Capital
-
Quarters > 3 > cash Flow > cash From Operations
209900000
Quarters > 3 > cash Flow > capital Expenditures
24100000
Quarters > 3 > cash Flow > cash From Investing
-89300000
Quarters > 3 > cash Flow > cash From Financing
20450000
Quarters > 3 > cash Flow > net Change In Cash
114250000
Quarters > 3 > cash Flow > currency_symbol
EUR
Quarters > 3 > ratios > PE
-
Quarters > 3 > ratios > PB
-
Quarters > 3 > ratios > ROE
-
Quarters > 3 > ratios > ROA
-
Quarters > 3 > ratios > FCF
185800000
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-
Quarters > 3 > health Score
46
Annuals > 0 > quarter
2022-12-31
Annuals > 0 > income Statement > revenue
-
Annuals > 0 > income Statement > cost Of Revenue
-
Annuals > 0 > income Statement > gross Profit
-
Annuals > 0 > income Statement > operating Expenses
-
Annuals > 0 > income Statement > operating Income
-
Annuals > 0 > income Statement > interest Expense
-
Annuals > 0 > income Statement > pretax Income
-
Annuals > 0 > income Statement > net Income
-
Annuals > 0 > income Statement > eps
-
Annuals > 0 > income Statement > dividends Per Share
99300000
Annuals > 0 > income Statement > shares Outstanding
-
Annuals > 0 > income Statement > income Tax Expense
112300000
Annuals > 0 > income Statement > EBITDA
-
Annuals > 0 > income Statement > operating Margin
-
Annuals > 0 > income Statement > total Other Income Expense Net
-
Annuals > 0 > income Statement > currency_symbol
EUR
Annuals > 0 > balance Sheet > cash
-
Annuals > 0 > balance Sheet > short Term Investments
-
Annuals > 0 > balance Sheet > receivables
673700000
Annuals > 0 > balance Sheet > inventories
284100000
Annuals > 0 > balance Sheet > total Current Assets
2397600000
Annuals > 0 > balance Sheet > property Plant Equipment
581400000
Annuals > 0 > balance Sheet > total Assets
-
Annuals > 0 > balance Sheet > payables
647100000
Annuals > 0 > balance Sheet > short Term Debt
-
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
1335400000
Annuals > 0 > balance Sheet > equity
-
Annuals > 0 > balance Sheet > currency_symbol
EUR
Annuals > 0 > cash Flow > net Income
647500000
Annuals > 0 > cash Flow > depreciation
222200000
Annuals > 0 > cash Flow > change In Working Capital
-
Annuals > 0 > cash Flow > cash From Operations
971400000
Annuals > 0 > cash Flow > capital Expenditures
96900000
Annuals > 0 > cash Flow > cash From Investing
-458600000
Annuals > 0 > cash Flow > cash From Financing
-164200000
Annuals > 0 > cash Flow > net Change In Cash
352600000
Annuals > 0 > cash Flow > currency_symbol
EUR
Annuals > 0 > ratios > PE
-
Annuals > 0 > ratios > PB
-
Annuals > 0 > ratios > ROE
-
Annuals > 0 > ratios > ROA
-
Annuals > 0 > ratios > FCF
874500000
Annuals > 0 > ratios > Piotroski FScore
1
Annuals > 0 > ratios > fcf Percent
-
Annuals > 0 > health Score
46
Annuals > 1 > quarter
2021-12-31
Annuals > 1 > income Statement > revenue
-
Annuals > 1 > income Statement > cost Of Revenue
-
Annuals > 1 > income Statement > gross Profit
-
Annuals > 1 > income Statement > operating Expenses
-
Annuals > 1 > income Statement > operating Income
-
Annuals > 1 > income Statement > interest Expense
0
Annuals > 1 > income Statement > pretax Income
-
Annuals > 1 > income Statement > net Income
-
Annuals > 1 > income Statement > eps
-
Annuals > 1 > income Statement > dividends Per Share
82900000
Annuals > 1 > income Statement > shares Outstanding
-
Annuals > 1 > income Statement > income Tax Expense
168200000
Annuals > 1 > income Statement > EBITDA
-
Annuals > 1 > income Statement > operating Margin
-
Annuals > 1 > income Statement > total Other Income Expense Net
-
Annuals > 1 > income Statement > currency_symbol
EUR
Annuals > 1 > balance Sheet > cash
-
Annuals > 1 > balance Sheet > short Term Investments
-
Annuals > 1 > balance Sheet > receivables
764500000
Annuals > 1 > balance Sheet > inventories
219400000
Annuals > 1 > balance Sheet > total Current Assets
1953800000
Annuals > 1 > balance Sheet > property Plant Equipment
647500000
Annuals > 1 > balance Sheet > total Assets
-
Annuals > 1 > balance Sheet > payables
594700000
Annuals > 1 > balance Sheet > short Term Debt
-
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
1228400000
Annuals > 1 > balance Sheet > equity
-
Annuals > 1 > balance Sheet > currency_symbol
EUR
Annuals > 1 > cash Flow > net Income
646600000
Annuals > 1 > cash Flow > depreciation
210000000
Annuals > 1 > cash Flow > change In Working Capital
-
Annuals > 1 > cash Flow > cash From Operations
909200000
Annuals > 1 > cash Flow > capital Expenditures
95900000
Annuals > 1 > cash Flow > cash From Investing
-344200000
Annuals > 1 > cash Flow > cash From Financing
-401200000
Annuals > 1 > cash Flow > net Change In Cash
169500000
Annuals > 1 > cash Flow > currency_symbol
EUR
Annuals > 1 > ratios > PE
-
Annuals > 1 > ratios > PB
-
Annuals > 1 > ratios > ROE
-
Annuals > 1 > ratios > ROA
-
Annuals > 1 > ratios > FCF
813300000
Annuals > 1 > ratios > Piotroski FScore
1
Annuals > 1 > ratios > fcf Percent
-
Annuals > 1 > health Score
46
Annuals > 2 > quarter
2020-12-31
Annuals > 2 > income Statement > revenue
2686200000
Annuals > 2 > income Statement > cost Of Revenue
490600000
Annuals > 2 > income Statement > gross Profit
2195600000
Annuals > 2 > income Statement > operating Expenses
-
Annuals > 2 > income Statement > operating Income
513400000
Annuals > 2 > income Statement > interest Expense
0
Annuals > 2 > income Statement > pretax Income
528800000
Annuals > 2 > income Statement > net Income
548000000
Annuals > 2 > income Statement > eps
-
Annuals > 2 > income Statement > dividends Per Share
83200000
Annuals > 2 > income Statement > shares Outstanding
-
Annuals > 2 > income Statement > income Tax Expense
-17800000
Annuals > 2 > income Statement > EBITDA
-
Annuals > 2 > income Statement > operating Margin
19.11250093068275
Annuals > 2 > income Statement > total Other Income Expense Net
-
Annuals > 2 > income Statement > currency_symbol
EUR
Annuals > 2 > balance Sheet > cash
312900000
Annuals > 2 > balance Sheet > short Term Investments
48900000
Annuals > 2 > balance Sheet > receivables
602800000
Annuals > 2 > balance Sheet > inventories
213900000
Annuals > 2 > balance Sheet > total Current Assets
1578800000
Annuals > 2 > balance Sheet > property Plant Equipment
646600000
Annuals > 2 > balance Sheet > total Assets
4317200000
Annuals > 2 > balance Sheet > payables
495200000
Annuals > 2 > balance Sheet > short Term Debt
2800000
Annuals > 2 > balance Sheet > long Term Debt
542700000
Annuals > 2 > balance Sheet > total Liabilities
2198200000
Annuals > 2 > balance Sheet > equity
2119000000
Annuals > 2 > balance Sheet > currency_symbol
EUR
Annuals > 2 > cash Flow > net Income
548000000
Annuals > 2 > cash Flow > depreciation
201600000
Annuals > 2 > cash Flow > change In Working Capital
-10000000
Annuals > 2 > cash Flow > cash From Operations
771300000
Annuals > 2 > cash Flow > capital Expenditures
79900000
Annuals > 2 > cash Flow > cash From Investing
-163700000
Annuals > 2 > cash Flow > cash From Financing
-307500000
Annuals > 2 > cash Flow > net Change In Cash
300600000
Annuals > 2 > cash Flow > currency_symbol
EUR
Annuals > 2 > ratios > PE
-
Annuals > 2 > ratios > PB
-
Annuals > 2 > ratios > ROE
25.86125530910807
Annuals > 2 > ratios > ROA
12.69341239692393
Annuals > 2 > ratios > FCF
691400000
Annuals > 2 > ratios > Piotroski FScore
4
Annuals > 2 > ratios > fcf Percent
0.25738962102598467
Annuals > 2 > health Score
72
Annuals > 3 > quarter
2019-12-31
Annuals > 3 > income Statement > revenue
2692800000
Annuals > 3 > income Statement > cost Of Revenue
488000000
Annuals > 3 > income Statement > gross Profit
2204800000
Annuals > 3 > income Statement > operating Expenses
-
Annuals > 3 > income Statement > operating Income
-35300000
Annuals > 3 > income Statement > interest Expense
0
Annuals > 3 > income Statement > pretax Income
-38600000
Annuals > 3 > income Statement > net Income
-50800000
Annuals > 3 > income Statement > eps
-
Annuals > 3 > income Statement > dividends Per Share
83200000
Annuals > 3 > income Statement > shares Outstanding
-
Annuals > 3 > income Statement > income Tax Expense
19600000
Annuals > 3 > income Statement > EBITDA
-
Annuals > 3 > income Statement > operating Margin
-1.3109031491384433
Annuals > 3 > income Statement > total Other Income Expense Net
-
Annuals > 3 > income Statement > currency_symbol
EUR
Annuals > 3 > balance Sheet > cash
137900000
Annuals > 3 > balance Sheet > short Term Investments
59300000
Annuals > 3 > balance Sheet > receivables
698000000
Annuals > 3 > balance Sheet > inventories
214000000
Annuals > 3 > balance Sheet > total Current Assets
1346500000
Annuals > 3 > balance Sheet > property Plant Equipment
679300000
Annuals > 3 > balance Sheet > total Assets
4306900000
Annuals > 3 > balance Sheet > payables
508500000
Annuals > 3 > balance Sheet > short Term Debt
14300000
Annuals > 3 > balance Sheet > long Term Debt
568200000
Annuals > 3 > balance Sheet > total Liabilities
2555800000
Annuals > 3 > balance Sheet > equity
1751100000
Annuals > 3 > balance Sheet > currency_symbol
EUR
Annuals > 3 > cash Flow > net Income
-50700000
Annuals > 3 > cash Flow > depreciation
161700000
Annuals > 3 > cash Flow > change In Working Capital
20400000
Annuals > 3 > cash Flow > cash From Operations
627700000
Annuals > 3 > cash Flow > capital Expenditures
144500000
Annuals > 3 > cash Flow > cash From Investing
-1157300000
Annuals > 3 > cash Flow > cash From Financing
550000000
Annuals > 3 > cash Flow > net Change In Cash
28100000
Annuals > 3 > cash Flow > currency_symbol
EUR
Annuals > 3 > ratios > PE
-
Annuals > 3 > ratios > PB
-
Annuals > 3 > ratios > ROE
-2.9010336360002285
Annuals > 3 > ratios > ROA
-1.1795026585246928
Annuals > 3 > ratios > FCF
483200000
Annuals > 3 > ratios > Piotroski FScore
2
Annuals > 3 > ratios > fcf Percent
0.17944147355912063
Annuals > 3 > health Score
43
Valuation > final Score
50
Valuation > verdict
Fair
Profitability > final Score
50
Profitability > verdict
Weak
Risk > final Score
50
Risk > verdict
High
Liquidity > metrics > Current Ratio
3.7051460361613353
Liquidity > metrics > Quick Ratio
3.266110338433009
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
50
Prev Valuations > 1
50
Prev Valuations > 2
50
Prev Profitabilities > 0
50
Prev Profitabilities > 1
50
Prev Profitabilities > 2
50
Prev Risks > 0
50
Prev Risks > 1
50
Prev Risks > 2
50
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T22:56:00.403Z
Earnings History > 0 > period
2025-12-31
Earnings History > 0 > report Date
2026-02-12
Earnings History > 0 > date
2025-12-31
Earnings History > 0 > before After Market
AfterMarket
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-
Earnings History > 0 > eps Estimate
4.36
Earnings History > 0 > eps Difference
0
Earnings History > 0 > surprise Percent
-
Earnings History > 1 > period
2025-09-30
Earnings History > 1 > report Date
2025-10-22
Earnings History > 1 > date
2025-09-30
Earnings History > 1 > before After Market
-
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
0
Earnings History > 1 > eps Estimate
0
Earnings History > 1 > eps Difference
0
Earnings History > 1 > surprise Percent
-
Earnings History > 2 > period
2025-06-30
Earnings History > 2 > report Date
2025-07-31
Earnings History > 2 > date
2025-06-30
Earnings History > 2 > before After Market
AfterMarket
Earnings History > 2 > currency
-
Earnings History > 2 > eps Actual
6.07
Earnings History > 2 > eps Estimate
-
Earnings History > 2 > eps Difference
0
Earnings History > 2 > surprise Percent
-
Earnings History > 3 > period
2025-03-31
Earnings History > 3 > report Date
2025-04-16
Earnings History > 3 > date
2025-03-31
Earnings History > 3 > before After Market
-
Earnings History > 3 > currency
-
Earnings History > 3 > eps Actual
1.37
Earnings History > 3 > eps Estimate
0
Earnings History > 3 > eps Difference
1.37
Earnings History > 3 > surprise Percent
-
Earnings History > 4 > period
2024-12-31
Earnings History > 4 > report Date
2025-02-13
Earnings History > 4 > date
2024-12-31
Earnings History > 4 > before After Market
-
Earnings History > 4 > currency
-
Earnings History > 4 > eps Actual
1.37
Earnings History > 4 > eps Estimate
0
Earnings History > 4 > eps Difference
1.37
Earnings History > 4 > surprise Percent
-
Earnings History > 5 > period
2024-09-30
Earnings History > 5 > report Date
2024-10-23
Earnings History > 5 > date
2024-09-30
Earnings History > 5 > before After Market
-
Earnings History > 5 > currency
-
Earnings History > 5 > eps Actual
0
Earnings History > 5 > eps Estimate
0
Earnings History > 5 > eps Difference
0
Earnings History > 5 > surprise Percent
-
Earnings History > 6 > period
2024-06-30
Earnings History > 6 > report Date
2024-07-25
Earnings History > 6 > date
2024-06-30
Earnings History > 6 > before After Market
-
Earnings History > 6 > currency
-
Earnings History > 6 > eps Actual
0
Earnings History > 6 > eps Estimate
0
Earnings History > 6 > eps Difference
0
Earnings History > 6 > surprise Percent
-
Earnings History > 7 > period
2024-03-31
Earnings History > 7 > report Date
2024-04-24
Earnings History > 7 > date
2024-03-31
Earnings History > 7 > before After Market
AfterMarket
Earnings History > 7 > currency
EUR
Earnings History > 7 > eps Actual
0
Earnings History > 7 > eps Estimate
0
Earnings History > 7 > eps Difference
0
Earnings History > 7 > surprise Percent
-
Earnings History > 8 > period
2023-12-31
Earnings History > 8 > report Date
2024-03-12
Earnings History > 8 > date
2023-12-31
Earnings History > 8 > before After Market
BeforeMarket
Earnings History > 8 > currency
EUR
Earnings History > 8 > eps Actual
0
Earnings History > 8 > eps Estimate
5.23
Earnings History > 8 > eps Difference
-5.23
Earnings History > 8 > surprise Percent
-100
Earnings History > 9 > period
2023-09-30
Earnings History > 9 > report Date
2023-10-26
Earnings History > 9 > date
2023-09-30
Earnings History > 9 > before After Market
-
Earnings History > 9 > currency
EUR
Earnings History > 9 > eps Actual
0
Earnings History > 9 > eps Estimate
0
Earnings History > 9 > eps Difference
0
Earnings History > 9 > surprise Percent
-
Earnings History > 10 > period
2023-06-30
Earnings History > 10 > report Date
2023-07-27
Earnings History > 10 > date
2023-06-30
Earnings History > 10 > before After Market
-
Earnings History > 10 > currency
EUR
Earnings History > 10 > eps Actual
4.98
Earnings History > 10 > eps Estimate
4.98
Earnings History > 10 > eps Difference
0
Earnings History > 10 > surprise Percent
0
Earnings History > 11 > period
2023-03-31
Earnings History > 11 > report Date
2023-04-27
Earnings History > 11 > date
2023-03-31
Earnings History > 11 > before After Market
-
Earnings History > 11 > currency
EUR
Earnings History > 11 > eps Actual
0
Earnings History > 11 > eps Estimate
0
Earnings History > 11 > eps Difference
0
Earnings History > 11 > surprise Percent
-
Earnings History > 12 > period
2022-12-31
Earnings History > 12 > report Date
2023-02-09
Earnings History > 12 > date
2022-12-31
Earnings History > 12 > before After Market
-
Earnings History > 12 > currency
EUR
Earnings History > 12 > eps Actual
0
Earnings History > 12 > eps Estimate
0
Earnings History > 12 > eps Difference
0
Earnings History > 12 > surprise Percent
-
Earnings History > 13 > period
2022-09-30
Earnings History > 13 > report Date
2022-10-27
Earnings History > 13 > date
2022-09-30
Earnings History > 13 > before After Market
-
Earnings History > 13 > currency
EUR
Earnings History > 13 > eps Actual
0
Earnings History > 13 > eps Estimate
0
Earnings History > 13 > eps Difference
0
Earnings History > 13 > surprise Percent
-
Earnings History > 14 > period
2022-06-30
Earnings History > 14 > report Date
2022-07-28
Earnings History > 14 > date
2022-06-30
Earnings History > 14 > before After Market
-
Earnings History > 14 > currency
EUR
Earnings History > 14 > eps Actual
0
Earnings History > 14 > eps Estimate
0
Earnings History > 14 > eps Difference
0
Earnings History > 14 > surprise Percent
-
Earnings History > 15 > period
2022-03-31
Earnings History > 15 > report Date
2022-04-27
Earnings History > 15 > date
2022-03-31
Earnings History > 15 > before After Market
-
Earnings History > 15 > currency
EUR
Earnings History > 15 > eps Actual
0
Earnings History > 15 > eps Estimate
0
Earnings History > 15 > eps Difference
0
Earnings History > 15 > surprise Percent
-
Earnings History > 16 > period
2021-12-31
Earnings History > 16 > report Date
2022-02-11
Earnings History > 16 > date
2021-12-31
Earnings History > 16 > before After Market
-
Earnings History > 16 > currency
EUR
Earnings History > 16 > eps Actual
0
Earnings History > 16 > eps Estimate
0
Earnings History > 16 > eps Difference
0
Earnings History > 16 > surprise Percent
-
Earnings History > 17 > period
2021-09-30
Earnings History > 17 > report Date
2021-10-21
Earnings History > 17 > date
2021-09-30
Earnings History > 17 > before After Market
-
Earnings History > 17 > currency
EUR
Earnings History > 17 > eps Actual
0
Earnings History > 17 > eps Estimate
0
Earnings History > 17 > eps Difference
0
Earnings History > 17 > surprise Percent
-
Earnings History > 18 > period
2021-06-30
Earnings History > 18 > report Date
2021-07-29
Earnings History > 18 > date
2021-06-30
Earnings History > 18 > before After Market
-
Earnings History > 18 > currency
EUR
Earnings History > 18 > eps Actual
0
Earnings History > 18 > eps Estimate
0
Earnings History > 18 > eps Difference
0
Earnings History > 18 > surprise Percent
-
Earnings History > 19 > period
2021-03-31
Earnings History > 19 > report Date
2021-04-22
Earnings History > 19 > date
2021-03-31
Earnings History > 19 > before After Market
-
Earnings History > 19 > currency
EUR
Earnings History > 19 > eps Actual
0
Earnings History > 19 > eps Estimate
0
Earnings History > 19 > eps Difference
0
Earnings History > 19 > surprise Percent
-
Earnings History > 20 > period
2020-12-31
Earnings History > 20 > report Date
2021-02-11
Earnings History > 20 > date
2020-12-31
Earnings History > 20 > before After Market
-
Earnings History > 20 > currency
EUR
Earnings History > 20 > eps Actual
0
Earnings History > 20 > eps Estimate
0
Earnings History > 20 > eps Difference
0
Earnings History > 20 > surprise Percent
-
Earnings History > 21 > period
2020-09-30
Earnings History > 21 > report Date
2020-10-22
Earnings History > 21 > date
2020-09-30
Earnings History > 21 > before After Market
-
Earnings History > 21 > currency
EUR
Earnings History > 21 > eps Actual
0
Earnings History > 21 > eps Estimate
0
Earnings History > 21 > eps Difference
0
Earnings History > 21 > surprise Percent
-
Earnings History > 22 > period
2020-06-30
Earnings History > 22 > report Date
2020-07-30
Earnings History > 22 > date
2020-06-30
Earnings History > 22 > before After Market
-
Earnings History > 22 > currency
EUR
Earnings History > 22 > eps Actual
0
Earnings History > 22 > eps Estimate
0
Earnings History > 22 > eps Difference
0
Earnings History > 22 > surprise Percent
-
Earnings History > 23 > period
2020-03-31
Earnings History > 23 > report Date
2020-04-22
Earnings History > 23 > date
2020-03-31
Earnings History > 23 > before After Market
-
Earnings History > 23 > currency
EUR
Earnings History > 23 > eps Actual
0
Earnings History > 23 > eps Estimate
0
Earnings History > 23 > eps Difference
0
Earnings History > 23 > surprise Percent
-
Earnings History > 24 > period
2019-12-31
Earnings History > 24 > report Date
2020-02-13
Earnings History > 24 > date
2019-12-31
Earnings History > 24 > before After Market
-
Earnings History > 24 > currency
EUR
Earnings History > 24 > eps Actual
0
Earnings History > 24 > eps Estimate
0
Earnings History > 24 > eps Difference
0
Earnings History > 24 > surprise Percent
-
Earnings History > 25 > period
2019-09-30
Earnings History > 25 > report Date
2019-10-24
Earnings History > 25 > date
2019-09-30
Earnings History > 25 > before After Market
-
Earnings History > 25 > currency
EUR
Earnings History > 25 > eps Actual
0
Earnings History > 25 > eps Estimate
0
Earnings History > 25 > eps Difference
0
Earnings History > 25 > surprise Percent
-
Earnings History > 26 > period
2019-06-30
Earnings History > 26 > report Date
2019-07-25
Earnings History > 26 > date
2019-06-30
Earnings History > 26 > before After Market
-
Earnings History > 26 > currency
EUR
Earnings History > 26 > eps Actual
0
Earnings History > 26 > eps Estimate
0
Earnings History > 26 > eps Difference
0
Earnings History > 26 > surprise Percent
-
Earnings History > 27 > period
2019-03-31
Earnings History > 27 > report Date
2019-04-24
Earnings History > 27 > date
2019-03-31
Earnings History > 27 > before After Market
-
Earnings History > 27 > currency
EUR
Earnings History > 27 > eps Actual
0
Earnings History > 27 > eps Estimate
0
Earnings History > 27 > eps Difference
0
Earnings History > 27 > surprise Percent
-
Earnings History > 28 > period
2018-12-31
Earnings History > 28 > report Date
2019-02-14
Earnings History > 28 > date
2018-12-31
Earnings History > 28 > before After Market
-
Earnings History > 28 > currency
EUR
Earnings History > 28 > eps Actual
0
Earnings History > 28 > eps Estimate
0
Earnings History > 28 > eps Difference
0
Earnings History > 28 > surprise Percent
-
Earnings History > 29 > period
2018-09-30
Earnings History > 29 > report Date
2018-10-25
Earnings History > 29 > date
2018-09-30
Earnings History > 29 > before After Market
-
Earnings History > 29 > currency
EUR
Earnings History > 29 > eps Actual
0
Earnings History > 29 > eps Estimate
0
Earnings History > 29 > eps Difference
0
Earnings History > 29 > surprise Percent
-
Earnings History > 30 > period
2018-06-30
Earnings History > 30 > report Date
2018-07-26
Earnings History > 30 > date
2018-06-30
Earnings History > 30 > before After Market
-
Earnings History > 30 > currency
EUR
Earnings History > 30 > eps Actual
2.86
Earnings History > 30 > eps Estimate
0
Earnings History > 30 > eps Difference
2.86
Earnings History > 30 > surprise Percent
-
Earnings History > 31 > period
2018-03-31
Earnings History > 31 > report Date
2018-04-26
Earnings History > 31 > date
2018-03-31
Earnings History > 31 > before After Market
-
Earnings History > 31 > currency
EUR
Earnings History > 31 > eps Actual
0
Earnings History > 31 > eps Estimate
2.77
Earnings History > 31 > eps Difference
-2.77
Earnings History > 31 > surprise Percent
-100
Earnings History > 32 > period
2017-12-31
Earnings History > 32 > report Date
2018-02-15
Earnings History > 32 > date
2017-12-31
Earnings History > 32 > before After Market
-
Earnings History > 32 > currency
EUR
Earnings History > 32 > eps Actual
0
Earnings History > 32 > eps Estimate
0
Earnings History > 32 > eps Difference
0
Earnings History > 32 > surprise Percent
-
Earnings History > 33 > period
2017-09-30
Earnings History > 33 > report Date
2017-10-26
Earnings History > 33 > date
2017-09-30
Earnings History > 33 > before After Market
-
Earnings History > 33 > currency
EUR
Earnings History > 33 > eps Actual
0
Earnings History > 33 > eps Estimate
0
Earnings History > 33 > eps Difference
0
Earnings History > 33 > surprise Percent
-
Earnings History > 34 > period
2017-06-30
Earnings History > 34 > report Date
2017-07-27
Earnings History > 34 > date
2017-06-30
Earnings History > 34 > before After Market
-
Earnings History > 34 > currency
EUR
Earnings History > 34 > eps Actual
0
Earnings History > 34 > eps Estimate
0
Earnings History > 34 > eps Difference
0
Earnings History > 34 > surprise Percent
-
Earnings History > 35 > period
2017-03-31
Earnings History > 35 > report Date
2017-04-27
Earnings History > 35 > date
2017-03-31
Earnings History > 35 > before After Market
-
Earnings History > 35 > currency
EUR
Earnings History > 35 > eps Actual
0
Earnings History > 35 > eps Estimate
0
Earnings History > 35 > eps Difference
0
Earnings History > 35 > surprise Percent
-
Earnings History > 36 > period
2016-12-31
Earnings History > 36 > report Date
2017-02-27
Earnings History > 36 > date
2016-12-31
Earnings History > 36 > before After Market
-
Earnings History > 36 > currency
EUR
Earnings History > 36 > eps Actual
0
Earnings History > 36 > eps Estimate
0
Earnings History > 36 > eps Difference
0
Earnings History > 36 > surprise Percent
-
Earnings History > 37 > period
2016-09-30
Earnings History > 37 > report Date
2016-10-26
Earnings History > 37 > date
2016-09-30
Earnings History > 37 > before After Market
-
Earnings History > 37 > currency
EUR
Earnings History > 37 > eps Actual
0
Earnings History > 37 > eps Estimate
0
Earnings History > 37 > eps Difference
0
Earnings History > 37 > surprise Percent
-
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injection for the treatment of pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer; Tazverik, a chemotherapy-free EZH2a inhibitor that is in phase III clinical trial for the treatment of second line follicular lymphoma; Tovorafenib that is in phase III clinical trial to treat first line pediatric Low-Grade Gliomas and is In phase II clinical trial for the treatment of relapsed/refractory pediatric Low-Grade Gliomas; and IPN01194 and IPN01195 that is in phase I to treat solid tumors. The company is also developing products for rare disease comprising Bylvay for the treatment of progressive familial intrahepatic cholestasis; Iqirvo, a peroxisome proliferator-activated receptor agonist to treat primary biliary cholangitis; NutropinAq, a liquid formulation of recombinant human growth hormone; Increlex, a recombinant human insulin-like growth factor; Fidrisertib that is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressive; Ritivixibat that is in phase II clinical trial to treat primary sclerosing cholangitis. In addition, it develops neuroscience products, such as Dysport that is in phase III clinical trial for the treatment of chronic and episodic migraine; and IPN10200 that is in phase II to treat aesthetic and therapeutic indications. The company has a partnership with Simcere Zaiming Pharmaceutical Co., Ltd. for the development of SIM0613, a protein expressed on varies tumor types and cancer-associated fibroblasts. The company was founded in 1929 and is headquartered in Paris, France.
Stock Price
€0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/A(Last Updated 2022-12-31)
Health Score
* Institutions hold a combined 0.00% of the total shares of Ipsen SA
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
2025-12-31
EPS Estimate
4.36
Date
2025-09-30
EPS Actual
0
EPS Estimate
0
EPS Difference
0
Surprise Percent
0%
(Last Updated 2022-12-31)
(Last Updated 2022-12-31)
Revenue
€ 0
Cost Of Revenue
€ 0
Gross Profit
€ 0
Operating Expenses
€ 0
Operating Income
€ 0
Interest Expense
€ 0
Pretax Income
€ 0
Net Income
€ 0
Income Tax Expense
€ 0
EBITDA
€ 0
Total Other Income Expense Net
€ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2022-12-31)
Cash
€ 0
Short Term Investments
€ 0
Receivables
€ 0
Inventories
€ 0
Total Current Assets
€ 0
Property Plant Equipment
€ 0
Total Assets
€ 0
Payables
€ 0
Short Term Debt
€ 0
Long Term Debt
€ 0
Total Liabilities
€ 0
Equity
€ 0
(Last Updated 2022-12-31)
Net Income
€ 0
Depreciation
€ 0
Change In Working Capital
€ 0
Cash From Operations
€ 0
Capital Expenditures
€ 0
Cash From Investing
€ 0
Cash From Financing
€ 0
Net Change In Cash
€ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.